
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte is a leader in the rapidly growing market for genomic diagnostics, with an expanding portfolio of advanced tests that improve patient outcomes and reduce costs. The recent results from the OPTIMA trial and the upcoming presentation at ASCO 2026 showcase the effectiveness of their Prosigna test in guiding chemotherapy decisions in breast cancer patients. With their strong revenue growth, favorable market conditions, and a promising pipeline of new tests, Veracyte has the potential for sustained long-term growth.
Bears say
Veracyte is well-positioned to capture meaningful market share in the evolving genomic diagnostics industry, with a solid portfolio consisting of its Decipher, Afirma, and Percepta tests. The company's upcoming entry into the MRD market for bladder cancer also presents potential growth opportunities. However, competition remains high in this industry, and Veracyte may experience challenges in gaining momentum with its kit-based strategy for expansion in Europe. With a current price target of $48, we believe that Veracyte's revenue growth of 12-16% may not meet investor expectations in the long term, limiting potential upside for the stock.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares